sorafenib has been researched along with thymosin in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (thymosin) | Trials (thymosin) | Recent Studies (post-2010) (thymosin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,649 | 120 | 683 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, CC; Lin, YT; Lu, HP | 1 |
| Chao, CC; Lin, YT | 1 |
2 other study(ies) available for sorafenib and thymosin
| Article | Year |
|---|---|
Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transcription Factors | 2015 |
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transfection | 2015 |